Table 1.

Membranous glomerulopathy in patients with hematopoietic stem cell transplantation

Patient no.	Demographics			HSCT			Clinical parameters at time of renal biopsy				Renal biopsy findings
	Age, yrs	Sex	Race	Indication for HSCT	GVHD	Interval between HSCT and renal biopsy, mo	sCr, mg/dl	UPCR, g/g	Serum albumin, g/dl	Edema	Segmental MGN	TBM deposits	PLA2R	NELL1	Mesangial deposits
1a	74	M	W	CMML	Y	36	1.46	6.8	2.5	Y	Y	Y	neg	pos	N
2	58	M		Leukemia NOS	Y	60	0.8	2.2	3.9	Y	Y	Y	NA	pos	Y
3	68	M		MDS	Y						N	N	NA	neg	N
4	70	F	W	AML	Y	54	0.8	3.3	2.6	Y	N	N	neg	neg	Y
5	53	M		AML	Y	48	1.3			Y	N	N	neg	neg	N
6	59	F	W	AML	Y	48	1.4	5	2.9	Y	N	N	pos	neg	N
7	55	M		CML	NA	60	2.3	15			N	N	NA	neg	NA
8	73	F	W	APL	Y	12	0.7	5.7	2.3	Y	N	N	neg	neg	N
9	68	M	W	MCL	Y		1.2	4.5	3.7	N	N	Y	neg	neg	N

AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; F, female; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant; M, male; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MGN, membranous glomerulopathy; N, no; neg, negative; NA, not available/not performed; NELL1, neural epidermal growth factor–like 1; NOS, not otherwise specified; pos, positive; PLA2R, phospholipase A2 receptor; sCr, serum creatinine; TBM, tubular basement membrane; UPCR, urine protein to creatinine ratio; W, white; Y, yes.

^aIndex case that is the subject of this report.